Table 6. Predictors of change in PCE between baseline and follow-up among operated cases.
| Kenya | Bangladesh | Philippines | |||||||||||
| N | Baseline mean PCE (95% CI) | Follow up mean PCE (95% CI) | Mean change (95% CI) | N | Baseline mean PCE (95% CI) | Follow up mean PCE (95% CI) | Mean change (95% CI) | N | Baseline mean PCE (95% CI) | Follow up mean PCE (95% CI) | Mean change (95% CI) | ||
| Age | ≤75 | 27 | 24 (17–32) | 32 (22–43) | 8 (−3–20) | 64 | 15 (13–17) | 23 (17–29) | 8 (2–14) | 56 | 20 (17–22) | 43 (15–72) | 24 (−5–52) |
| >75 | 38 | 20 (15–26) | 27 (17–37) | 7 (−3–17) | 35 | 19 (7–31) | 23 (14–31) | 4 (−8–16) | 43 | 29 (19–38) | 47 (33–60) | 18 (3–33) | |
| p-value | 0.34 | 0.30 | 0.88 | 0.92 | 0.80 | 0.51 | 0.11 | 0.03 | 0.72 | ||||
| Sex | Male | 33 | 20 (15–24) | 22 (17–27) | 2 (−4–8) | 47 | 18 (9–27) | 25 (18–31) | 7 (−3–16) | 38 | 21 (16–25) | 34 (22–47) | 14 (3–25) |
| Female | 32 | 24 (16–32) | 38 (24–51) | 13 (0–27) | 52 | 15 (12–18) | 22 (15–28) | 7 (0–13) | 61 | 26 (19–32) | 51 (25–78) | 25 (−2–53) | |
| p-value | 0.48 | 0.13 | 0.12 | 0.83 | 0.30 | 0.99 | 0.28 | 0.27 | 0.41 | ||||
| Married | Yes | 35 | 20 (14–26) | 24 (15–34) | 4 (−8–16) | 48 | 20 (11–28) | 23 (18–27) | 4 (−5–11) | 43 | 22 (19–26) | 35 (24–46) | 13 (3–23) |
| No | 28 | 23 (16–30) | 35 (24–46) | 12 (3–21) | 51 | 13 (11–15) | 23 (15–31) | 10 (2–18) | 53 | 25 (17–33) | 53 (23–84) | 28 (−3–60) | |
| p-value | 0.30 | 0.10 | 0.26 | 0.09 | 0.29 | 0.24 | 0.53 | 0.50 | 0.35 | ||||
| Literate | Yes | 19 | 25 (18–32) | 28 (19–36) | 3 (−7–12) | 8 | 17 (13–21) | 25 (19–32) | 8 (0–16) | 84 | 24 (19–30) | 49 (29–68) | 24 (4–44) |
| No | 46 | 21 (15–26) | 30 (21–40) | 10 (0–19) | 91 | 16 (12–21) | 23 (18–28) | 6 (0–13) | 15 | 19 (15–24) | 23 (13–33) | 3 (−8–15) | |
| p-value | 0.15 | 0.58 | 0.30 | 0.24 | 0.01 | 0.68 | 0.56 | 0.04 | 0.07 | ||||
| Baseline self-rated health | <median | 19 | 17 (13–20) | 24 (15–33) | 8 (1–14) | 47 | 15 (12–19) | 23 (16–29) | 8 (1–14) | 59 | 25 (18–32) | 33 (26–41) | 8 (−1–18) |
| ≥median | 46 | 24 (18–30) | 32 (22–41) | 7 (−2–17) | 52 | 18 (10–26) | 23 (16–30) | 5 (−4–15) | 40 | 22 (18–26) | 62 (21–103) | 40 (0–80) | |
| p-value | 0.23 | 0.45 | 0.98 | 0.69 | 0.71 | 0.66 | 0.72 | 0.18 | 0.13 | ||||
| Baseline PCE | <median | 28 | 10 (9–11) | 26 (12–39) | 16 (3–29) | 59 | 9 (9–10) | 18 (13–23) | 9 (4–14) | 61 | 14 (13–16) | 31 (24–38) | 17 (10–24) |
| ≥median | 37 | 31 (25–37) | 33 (24–41) | 1 (−7–9) | 40 | 27 (17–37) | 30 (21–39) | 3 (−9–16) | 38 | 39 (29–49) | 67 (24–110) | 28 (−16–73) | |
| p-value | <0.0001 | 0.03 | 0.05 | <0.001 | 0.0003 | 0.40 | <0.0001 | 0.002 | 0.60 | ||||
| Baseline VA | MVI/SVI | 38 | 20 (15–27) | 28 (21–36) | 8 (1–15) | 45 | 15 (12–18) | 20 (17–23) | 5 (2–9) | 47 | 24 (15–33) | 53 (19–87) | 29 (−6–64) |
| Blind | 27 | 24 (17–32) | 31 (17–45) | 7 (−8–22) | 54 | 18 (10–25) | 25 (17–34) | 8 (−2–18) | 52 | 23 (19–27) | 37 (26–48) | 14 (4–24) | |
| p-value | 0.22 | 0.96 | 0.90 | 0.77 | 0.89 | 0.66 | 0.45 | 0.59 | 0.41 | ||||
| Outcome VA | 6/6–6/18 | 41 | 25 (19–32) | 33 (22–44) | 8 (−3–19) | 83 | 17 (12–22) | 22 (17–26) | 5 (−1–11) | 71 | 24 (18–30) | 47 (23–70) | 23 (−1–47) |
| <6/18 | 24 | 16 (13–20) | 24 (17–31) | 7 (0–14) | 16 | 14 (10–17) | 29 (10–48) | 16 (−3–34) | 28 | 23 (18–29) | 40 (28–51) | 16 (5–28) | |
| p-value | 0.11 | 0.40 | 0.95 | 0.65 | 0.43 | 0.17 | 0.58 | 0.51 | 0.62 | ||||
| Eyes operated | 1 | 44 | 21 (16–25) | 27 (20–35) | 7 (0–13) | 75 | 14 (12–16) | 23 (17–29) | 9 (3–15) | 67 | 24 (18–31) | 36 (27–44) | 11 (2–21) |
| 2 | 21 | 25 (15–34) | 34 (17–50) | 9 (−10–29) | 24 | 24 (7–41) | 23 (16–30) | −1 (−16–14) | 30 | 21 (17–26) | 66 (12–120) | 45 (−9–99) | |
| p-value | 0.56 | 0.37 | 0.80 | 0.11 | 0.66 | 0.21 | 0.66 | 0.36 | 0.22 | ||||